Looks like PAR copped a blast from ASX this morning for going to the media before them. Read the PAR patents for this. It's for bone marrow edema, not osteoarthritis directly. An early version said for BME not related to OA. I can't see how they are going to exclusively license.
Osteoarthritis medicine, page-29
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
52.0¢ |
Change
0.060(13.0%) |
Mkt cap ! $82.30M | |||
| Open | High | Low | Value | Volume |
| 47.0¢ | 56.0¢ | 40.0¢ | $4.475M | 8.971M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12150 | 49.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.0¢ | 39994 | 1 |
View Market Depth
| Last trade - 16.10pm 26/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |
